Adherent indomethacin-sensitive suppressor cells in malignant melanoma
Correlation with clinical status
Original Articles
Received:
Accepted:
- 13 Downloads
- 2 Citations
Summary
Twenty-five patients with malignant melanoma were studied to determine the mechanisms underlying decreased cellular immunity in this disease. Sixteen patients were examined following surgical resections of tumor, and nine patients had evidence of metastases. Patients with metastatic disease (group II) had decreased lymphocyte transformation to concanavalin A (48,255±30,074) compared with controls (83,550±41,277) and patients free of disease (group I) 110,231±59,990) (P>0.01). Rigorous depletion of monocytes by adherent techniques resulted in an improvement in blastogenesis in seven of nine group II patients, whereas controls and group I patients had marked decreases in reactivity. Indomethacin also improved lymphocyte reactivity; a mean of 166.4% was recorded in five metastatic disease patients studied, as against a mean of 2% in group I and 9.65% in controls. In seven patients followed serially the presence of adherent suppressor cells tended to correlate with progressive disease, shorter survival, and decreased skin test reactivity.
Keywords
Malignant Melanoma Cancer Research Surgical Resection Metastatic Disease Indomethacin
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Preview
Unable to display preview. Download preview PDF.
References
- 1.Berkelhammer J, Mastrangelo MJ, Laucius JF, Bodurtha AJ, Prehn RT (1975) Sequential in vitro reactivity of lymphocytes from melanoma patients receiving immunotherapy as compared with the reactivity of lymphocytes from healthy donors. Int J Cancer 16:571Google Scholar
- 2.Bodurtha AJ, Chee DD, Laucius JF, Mastrangelo MJ, Prehn RT (1975) Clinical and immunological significance of human melanoma cytotoxic antibody. Cancer Res 35:189Google Scholar
- 3.Camacho ES, Pinsky CM, Wanebo HJ et al. (1977) DNCB reactivity and prognosis in 358 patients with malignant melanoma (abstract). Proc Am Assoc Cancer Res 18:226Google Scholar
- 4.Canevari S, Fossati G, Della Porta G, Balzarini GP (1975) Humoral cytotoxicity in melanoma patients and its correlation with extent and course of the disease. Int J Cancer 16:722Google Scholar
- 5.DeGast GC, The TH, Koops HS, Huiges HA, Oldhoff J, Nieweg HO (1975) Humoral and cell-mediated immune response in patients with malignant melanoma. I. In vitro lymphocytic reactivity to PHA and antigens following immunization. Cancer 36:1289Google Scholar
- 6.Eilber FR, Morton DL (1970) Impaired immunologic reactivity and recurrence following cancer surgery. Cancer 25:362Google Scholar
- 7.Einhorn LH, Burgess MA, Vallejos C et al. (1974) Prognostic correlations and response to treatment in advanced metastatic malignant melanoma. Cancer Res 34:1995Google Scholar
- 8.Galli V, Schlesinger M (1974) The formation of stable E rosettes after neuraminidase treatment of either human peripheral blood lymphocytes or sheep red blood cells. J Immunol 112:1628Google Scholar
- 9.Golub SH, O'Connell TX, Morton DL (1977) Correlation of in vivo and in vitro assays of immunocompetence in cancer patients. Cancer Res 34:1833Google Scholar
- 10.Goodwin JS, Messner RP, Bankhurst AD, Peake GT, Saiki JH, Williams RC (1977) Prostaglandin producing suppressor cells in Hodgkin's disease. N Engl J Med 297:963Google Scholar
- 11.Goodwin JS, Murphy S, Bankhurst AD, Selinger DS, Messner RP, Williams RC Jr (1978) Partial reversal of the cellular immune defect in common variable immune deficiency with indomethacin. J Clin Lab Immunol 1:197Google Scholar
- 12.Gross NS, Eddie-Quartey AC (1976) Monitoring of immunologic status of patients receiving BCG therapy for malignant disease. Cancer 37:2183Google Scholar
- 13.Gutterman JU, Mavligit G, Gottlieb JA et al. (1974) Chemoimmunotherapy of disseminated malignant melanoma with dimethyl triazeno imidazole carboxamide and bacillus Calmette-Gúerin. N Engl J Med 291:592Google Scholar
- 14.Han T, Takita H (1979) Depression of T lymphocyte response by non-T suppressor cells in lung cancer patients. A possible prognostic value of suppressor cell activity. Cancer 44:2090Google Scholar
- 15.Hellstrom I, Hellstrom KE, Sjogren HO, Warner GA (1971) Demonstration of cell mediated immunity to human neoplasia of various histologic types. Int J Cancer 7:1Google Scholar
- 16.Heppner GH, Stohlback L, Byrne M, Cummings FJ, McDonough E, Calabresi P (1973) Cell-mediated and serum blocking reactivity to tumor antigens in patients with malignant melanoma. Int J Cancer 11:245Google Scholar
- 17.Herr HW (1980) Suppressor cells in immunodepressed bladder and prostate cancer patients. J Urol 123:635Google Scholar
- 18.Jerrels TR, Dean JH, Richardson GL, McCoy JL, Heberman RB (1978) Role of suppressor cells in depression of in vitro lymphoproliferative responses of lung cancer and breast cancer patients. J Natl Cancer Inst 61:1001Google Scholar
- 19.Koller CA, King GW, Hurtubise PE, Sagone AL, LoBuglio AF (1973) Characterization of glass-adherent human mononuclear cells. J Immunol 111:1610Google Scholar
- 20.Kurland J, Bockman R (1978) Prostaglandin E production by human blood monocytes and mouse peritoneal macrophages. J Exp Med 147:952Google Scholar
- 21.Lewis MG (1967) Possible immunological factors in human malignant melanoma in Uganda. Lancet 2:921Google Scholar
- 22.Lewis MG, Ikonopisov RL, Nairn RC et al. (1969) Tumor-specific antibodies in human malignant melanoma and their relationship to the extent of disease. Br Med J 3:547Google Scholar
- 23.Li CY, Lam KW, Yam LT (1973) Esterases in human leukocytes. J Histochem Cytochem 21:1Google Scholar
- 24.Lynch NR, Salomon JC (1979) Tumor growth inhibition and potentiation of immunotherapy by indomethacin in mice. J Natl Cancer Inst 62:117Google Scholar
- 25.Morton DL, Malmgren FA, Holmes EC, Ketcham AS (1968) Demonstration of antibodies against human malignant melanoma by immunofluorescence. Surgery 64:233Google Scholar
- 26.Nathanson L, Hall T, Farber S (1967) Biological aspects of human malignant melanoma. Cancer 20:650Google Scholar
- 27.Ninneman JL (1978) Melanoma-associated immunosuppression through B cell activation of suppressor T cells. J Immunol 120:1573Google Scholar
- 28.Oldham RK, Djeu JY, Cannon GB, Siwarski D, Herberman RB (1975) Cellular microcytotoxicity in human tumor systems: Analysis of results. J Natl Cancer Inst 55:1305Google Scholar
- 29.Plescia DJ, Smith AH, Grinwich K (1975) Subversion of immune system by tumor cells and role of prostaglandins. Proc Natl Acad Sci 72:1848Google Scholar
- 30.Pritchard DJ, Ritts RE Jr, Taylor WF, Miller GC (1978) A prospective study of immune responsiveness in human melanoma. I. Assessment of initial pretreatment status with stage of disease. Cancer 41:2165Google Scholar
- 31.Romsdahl MM, Cox IS (1970) Human malignant melanoma antibodies demonstrated by immunofluorescence. Arch Surg 109:491Google Scholar
- 32.Santoro MG, Philpott GW, Jaffe BM (1976) Inhibition of tumor growth in vivo and in vitro by prostaglandin E. Nature 263:777Google Scholar
- 33.Seigler HE, Shingleton WW, Metzgar RS et al. (1972) Non-specific and specific immunotherapy in patients with melanoma. Surgery 72:162PubMedGoogle Scholar
- 34.Smith LJ, Stehlin JS Jr (1965) Spontaneous regression of primary malignant melanomas with regional metastases. Cancer 18:1399Google Scholar
- 35.Zembala M, Mytar B, Popiela T, Asherson GL (1977) Depressed in vitro peripheral blood lymphocyte response to mitogens in cancer patients. Int J Cancer 19:604Google Scholar
- 36.Zigelboim J, Corey F, Parker NH, Calcateria T, Ward P, Fahey JL (1979) Immunologic evaluation of patients with advanced head and neck cancer receiving weekly chemoimmunotherapy. Cancer 44:117Google Scholar
Copyright information
© Springer-Verlag GmbH & Co KG 1981